# Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England

4	Samuel Clifford PhD <sup>1,2</sup> , Pauline Waight BSc <sup>3</sup> , Jada Hackman BSc <sup>1,2</sup> , Stephane Hué PhD <sup>1,2</sup> ,					
5	Charlotte M Gower DPhil <sup>3</sup> , Freja CM Kirsebom PhD <sup>3</sup> , Catriona Skarnes MSc <sup>3</sup> , Louise Letley					
6	MSc <sup>3</sup> , Jamie Lopez Bernal PhD <sup>3</sup> , Nick Andrews PhD <sup>3</sup> , Stefan Flasche PhD <sup>1,2,+</sup> , Elizabeth Miller					
7	FRCPath <sup>2,3,+</sup>					
8	1. Centre for mathematical modelling of infectious diseases, London School of Hygiene & Tropical Medicine,					
10	<ol> <li>Department for infectious disease epidemiology, London School of Hygiene &amp; Tropical Medicine,</li> <li>LONDON WG1E 7117</li> </ol>					
12	<ol> <li>National Infection Service, UK Health Security Agency, LONDON NW9 5EQ</li> </ol>					
13	+ Contributed equally					
14	Corresponding author, Liz.Miller@lshtm.ac.uk, LSHTM, UK HSA					

# 15 Summary

- 16 <u>Background</u>: The ability of SARS-CoV-2 vaccines to protect against infection and onward
- 17 transmission determines whether immunisation can control global circulation. We estimated
- 18 effectiveness of BNT162b2 and ChAdOx1 vaccines against acquisition and transmission of the
- 19 Alpha and Delta variants in a prospective household study in England.
- 20 <u>Methods</u>: Adult index cases in the community and their household contacts took oral-nasal swabs
- 21 on days 1, 3 and 7 after enrolment. Swabs were tested by RT-qPCR with genomic sequencing
- 22 conducted on a subset. We used Bayesian logistic regression to infer vaccine effectiveness against
- 23 acquisition and transmission, adjusted for age, vaccination history and variant.
- 24 <u>Findings</u>: Between 2 February 2021 and 10 September 2021 213 index cases and 312 contacts
- 25 were followed up. After excluding households lacking genomic proximity (N=2) or with unlikely

26	serial intervals (N=16), 195 households with 278 contacts remained of whom 113 (41%) became
27	PCR positive. Delta lineages had 1.64 times the risk (95% Credible Interval: 1.15 – 2.44) of
28	transmission than Alpha; contacts older than 18 years were 1.19 times (1.04 - 1.52) more likely to
29	acquire infection than children. Effectiveness of two doses of BNT162b2 against transmission of
30	Delta was 31% (-3%, 61%) and 42% (14%, 69%) for ChAdOx1, similar to their effectiveness for
31	Alpha. Protection against infection with Alpha was higher than for Delta, 71% (12%,95%) vs 24%
32	(-2%, 64%) respectively for BNT162b2 and 26% (-39%, 73%) vs 14% (-5%, 46%) respectively for
33	ChAdOx1.
34	Interpretation: BNT162b2 and ChAdOx1 reduce transmission of the Delta variant from
35	breakthrough infections in the household setting though their protection against infection is low.
36	Funding: This study was funded by the UK Health Security Agency (formerly Public Health

## 38 Introduction

37

England) as part of the COVID-19 response.

The rapid development of safe and effective COVID-19 vaccines using both novel and traditional 39 40 platforms, is an unprecedented scientific achievement. The United Kingdom was the first 41 country to launch a national COVID-19 vaccination programme with the rollout of the Pfizer-42 BioNTech mRNA vaccine (BNT162b2) on 8th December 2020, followed shortly after by the 43 Oxford AstraZeneca adenovirus vector vaccine (ChAdOx1). By September 2021, over 40% of the world's population had received at least one dose of a COVID-19 vaccine, whether an mRNA, 44 adenovirus vector, or inactivated whole virion vaccine.<sup>1</sup> In most countries, vaccine deployment 45 has been focussed on direct protection of those individuals at greatest risk of a severe outcome of 46 47 SARS-CoV-2 infection including the elderly and those with co-morbidities. Health care workers 48 and others who, if infected, pose a transmission risk to vulnerable individuals, have also been 49 identified as a priority group for vaccination.

50 The primary outcome of the efficacy trials of the currently authorised COVID-19 vaccines was 51 symptomatic laboratory confirmed SARS-CoV-2 infection, with little information generated on 52 protection against severe COVID-19 infection nor on the ability of the vaccines to prevent

53	onward transmission in those infected. There is now a growing body of evidence from
54	observational studies showing high protection against severe COVID-19 from inactivated whole
55	virion, mRNA, and adenovirus vector vaccines but information on protection against
56	transmission is still limited. <sup>2</sup> Attempts have been made to infer protection against transmission by
57	comparing the viral load in the nasopharynx of vaccinated individuals with breakthrough
58	infections with that in unvaccinated cases, using Ct values as a proxy. <sup>3</sup> Other approaches have
59	used routine diagnostic PCR testing data, constructing households based on individuals'
60	addresses or identifying them with contact tracing, and to estimate secondary attack rates by
61	vaccination status of the index case. However, these studies are potentially subject to
62	ascertainment bias as they are reliant on the testing behaviour of household contacts. <sup>4–6</sup>
63	Here we report the results of a prospective household transmission study set up by Public Health
64	England (now the UK Health Security Agency) in January 2021 to assess the effect of the
65	vaccination history of index cases with COVID-19 on transmission of SARS-CoV-2 to
66	household contacts, and the protection afforded to vaccinated contacts under conditions of
67	household exposure.

## 68 Methods

69 Data

#### 70 Households

71 Details of household recruitment, ethics, data governance and laboratory testing has been 72 reported elsewhere.<sup>7</sup> In brief, infected index cases, identified via Pillar 2 community testing, and 73 their consenting household contacts are recruited by study nurses, on average, 3 days after their 74 initial PCR test. The vaccination status of index cases and their household contacts is obtained by 75 data linkage with the National Immunisation Management System (NIMS) and checked with participants by the study nurse at the time of recruitment. Self-testing kits for the index case and 76 77 household contacts to take combined nose and throat swabs on recruitment (Day 1), Day 3 and 78 Day 7 are couriered to households and subsequently tested by dual target PCR at PHE Colindale 79 (ORF and E genes). PCR positive swabs are sequenced as part of the COG-UK initiative.<sup>8</sup>

80 Household contacts were defined as infected if one or more swabs was PCR positive.

81 The household transmission study is ongoing and inclusion in this analysis is based on 82 participants having returned at least one swab, being either unvaccinated or vaccinated with one 83 or two doses of either BNT162b2 or ChAdOx1 with the vaccination dates available, and the age 84 at time of recruitment and the date of onset of symptoms (fever, cough, runny nose, sore throat, 85 shortness of breath, loss of taste or smell, nausea, diarrhea, muscle/body pain, headache or other) 86 recorded.

## 87 Statistical Analysis

All analysis was conducted in R 4.1.1<sup>9</sup> with Bayesian models fit using the rjags package.<sup>10</sup> The secondary attack rate (SAR) for each combination of case and contact is estimated here by predicting the probability an unseen contact acquires an infection from an infected case given the vaccination history and age of each. The effects of vaccination are presented in the results as risk ratios (RRs) for each vaccine product and number of doses compared to the unvaccinated group of the same age and household variant. The predicted SARs and RRs are summarised with medians and 95% credible intervals.

#### 95 Household secondary attack rate

We fit a Bayesian hierarchical linear model with Bernoulli likelihood for the probability that a 96 97 household contact of an index case acquires a SARS-CoV-2 infection within a week of 98 recruitment. The model estimates both a protective effect for vaccinated contacts against 99 infection and a reduction in transmission for vaccinated cases, which are assumed to be 100 independent. The effect of the first dose is assumed to only occur 21 days after the vaccination is received, and an additional effect of the second dose requires at least 7 days have passed since the 101 102 second vaccination as in the SIREN study which considers the effectiveness of BNT162b2 in 103 healthcare workers in England<sup>11</sup>. These effects are assumed to depend on the vaccine product, and 104 number of doses thereof, received by both the index case and the contact (Table A1). The 105 probability of acquiring infection is also assumed to depend on the age of both the case and 106 contact, and the circulating lineage. Vaccine efficacies are calculated as 1-relative risk in household

107	secondary attack rates (SARs). For such the SARs were sampled during the MCMC sampling, for
108	each combination of variant and case and contact vaccine status (1 or 2 doses for each product)
109	and age group, against a baseline of that case-contact pair and variant in the absence of any
110	vaccination.

#### 111 Lineage

At the start of data collection, the B.1.1.7 (Alpha) SARS-CoV-2 variant was most prevalent in the United Kingdom, and an increasing proportion of swabs sequenced by Pillar 2 testing were identified as B.1.617.2 (Delta) variant over time<sup>12</sup>. Where sequencing was not available to determine the variant for a positive swab, the probability that it was the Delta variant was estimated from the date of sampling and a logistic regression model fit to the number of weekly cases identified through Pillar 2 that were either Alpha or Delta variant.

#### 118 Participants' age

119 Vaccine eligibility and type is correlated with age and date of vaccination. This is because from 120 7th April 2021 the BNT162b2 vaccine was recommended for under 30 years olds in preference to 121 ChadOx1 with extension to 30-40 year olds from 7th May 2021<sup>13</sup> and also because, apart from 122 those in high risk groups, vaccination was not offered to the general 16-17 year old population until August 2021<sup>14</sup> and the general 12-15 year old population until September 2021<sup>15</sup>. We 123 124 account for age in the model by considering that children under 18 will have decreased 125 susceptibility to infection, compared to adults,<sup>16</sup> and that older adults are more likely to 126 transmit.<sup>17</sup> While the study did not specifically recruit only adult index cases, the minimum age of 127 index cases was 21. The median age of index cases was 48 years and so we split adults into younger 128 (18-49) and older (50+) age groups. Very few participants were older than 65 years so we do not distinguish between 50-64 and 65+ year olds. We did not adjust for prior infection status as 129 information on this was incomplete at the time of data lock, nor for gender as this was previously 130 131 shown not to be a factor in determining household transmission.<sup>7</sup> Table A2 shows the age and vaccine status breakdown of index cases and their household contacts. 132

#### 133 Infection history dynamics

PCR positivity relative to the onset of symptoms was estimated using data from all symptomatic
cases and contacts, with pseudo-absences generated to simulate the time of infecting exposure.
Comparison is made for each combination of vaccine product, number of doses, and variant
against the corresponding unvaccinated group. Details of this modelling can be found in the
Appendix.

#### 139 Identification of non-household transmission

As per the study design, the index case for each household was by default considered to be the individual who presented for Pillar 2 testing. To reduce the risk of misclassification bias we excluded from the analyses all households where both the index case and an infected household contact were symptomatic and the index case's symptoms appeared more than two days after the contact's symptoms.

To further reduce the potential for misclassification bias, a phylogenetic approach was used to identify apparent secondary cases in the household who were in fact infected elsewhere. If none of the sequences from a contact clustered with at least one of the sequences from the household's index case, then this was considered as evidence for an infection acquired outside of the household; therefore, the contact was excluded from the downstream analysis. Details of the phylogenetic approach can be found in the Appendix.

# 151 Role of funding source

152 The study sponsors had no role in the collection, analysis, and interpretation of data; in the 153 writing of the report; and in the decision to submit the paper for publication

# 154 **Results**

By September 10th, 2021, a total of 213 index cases and 312 contacts had been recruited and met

156 the criteria for inclusion at that time. Two contacts were removed due to lack of genomic

157 proximity (outlined below), which resulted in the removal of each of their households as there

158 were no further contacts. The serial interval was 2 (95% range: -6 - 10) days. Sixteen households

159 with their respective index cases and a total of 32 contacts were excluded from the main analysis

- 160 because at least one infected household contact presented symptoms more than 2 days before the
- 161 index case. Thus, the main analysis was performed on 195 index cases and their 278 contacts.
- 162 Households had between 1 and 7 contacts, with a mean of 2.2, median of 2, and standard
- 163 deviation of 1.2. The mode number of household contacts was 1.
- 164 Of the included individuals, 175 index cases (90%) and 113 (41%) contacts tested positive for
- 165 SARS-CoV-2 at least once in the week since recruitment. Sequencing information was available
- 166 for 122 (69%) and 81 (71%) of those, respectively.
- 167 Most (77%) index cases had received at least one dose of a vaccine at enrolment, whereas 52% of
- 168 household contacts had (Table A1). 24% of contacts were less than 18 years old, and therefore not
- 169 eligible for vaccination at the time. The proportion of at least partially vaccinated adult
- 170 household contacts was 69%. Only 10 index cases (5%) were asymptomatic, reflecting the bias of
- 171 Pillar 2 testing in the UK towards detecting mostly symptomatic infections.

#### 172 Prevalence of lineages

- 173 Of the 195 index cases analysed here, 99 were identified as infected with B.1.1.7 (Alpha), 24 with
- 174 B.1.617.2 (Delta), 20 did not test positive again after recruitment, and 52 were of unknown
- lineage as their PCR-positive swabs had not yet been sequenced (Figure A3). Of the 72
- 176 individuals without information on the infecting lineage, we estimated that 18 were likely of
- 177 Alpha and 54 were likely of Delta lineage based on the date of sampling (Figures A2, A3) and the
- 178 national prevalence of lineages at the time. That is, 60% of index cases had an Alpha variant
- 179 infection and the remainder were Delta.

## 180 Identification of non-household transmission

181 Sequencing information for both index case and contact was available for 92 PCR positive case-

- 182 contact pairs across 79 households. In total, 345 whole-genome sequences (including longitudinal
- 183 samples) were available for analyses, a majority of which were of Alpha variant (82.6%) and the
- 184 remainder were Delta (17.4%).
- 185



186

Figure 1: Maximum-likelihood phylogeny of household index cases and contacts' sequences 187 188 with 1,000 ultrafast bootstrap replicates rooted to the reference sequence with a scaled bar of 189 2 SNP (6.6 × 10<sup>-5</sup> substitutions/site). The dotted line at bottom left indicates where a single 190 long branch was collapsed for visualisation. The non-grey shading on the outer ring represents 191 non-clustered households where sequences are coloured by their households. HH002 and HH007 were the only households where none of the contacts' sequences clustered with their 192 household's index case's and this is evidence the contact could have acquired the infection 193 194 elsewhere and is thus excluded from the analysis.

The phylogeny provided evidence that in two households the contact of the recruited index case had acquired infection elsewhere (Figure 1, households HH002 and HH007). Five households that did not form unique clusters in the phylogeny did not meet the exclusion criteria: in two a sequence from an index case did not cluster with the remaining household sequences but another sequence from the same index case did (HH004 and HH006) while the other three households did not have sufficient bootstrap support to be a part of a cluster (HH001, HH003, and HH005). Of the remaining households, 72 (91%), formed unique, household-specific clusters

that included all and only sequences of members of the household, indicating likely directtransmission within the household.

## Age and lineage effects

We estimate that in the absence of vaccination of either case or contacts, Delta lineage infections
were much more transmissible from non-elderly adult cases to adult contacts within the
household than Alpha lineage infections (Risk Ratio: 1.64, 95% Credible Interval: 1.15, 2.44).
Children younger than 18 years old were less likely as adults to acquire a Delta infection from
non-elderly adults (RR: 0.84, 95%: 0.66, 0.96). Compared to a baseline of Delta index cases aged
between 18 and 49, those 50 and over had 1.06 times the risk of transmitting their infection (95%:
1.00, 1.23).

## 212 Effectiveness of vaccination

213 Either one or two doses of BNT162b2 provide a protective effect against infection from a

symptomatic index case with Alpha variant SARS-CoV-2 with a vaccine effectiveness of 53%,

215 (95% credible interval: 7%, 83%) and 71% (95% CrI: 12%, 95%), respectively (Table 1, Figure A4).

216 At 4% (-21%, 44%) and 24% (-2%, 64%) the effectiveness of one and two doses of BNT162b2

against infection with the Delta variant was lower than against Alpha and was similar to the

218 effectiveness offered by ChAdOx1 to either variant (Table A5) which, after two doses, had

219 effectiveness against Alpha of 26% (-39%, 73%) and against Delta of 14% (-5%, 46%).

220 We estimate that the effectiveness of one and two doses of BNT162b2 against onward

transmission if infected with the Alpha variant was 26% (-11%, 54%) and 57% (5%, 85%) and for

222 Delta variant one and two doses reduce transmission by 9% (-16%, 49%) and 37% (4%, 65%). RRs

for the protective effect of BNT162b2 over ChAdOx1 for one and two doses of against both

Alpha and Delta variants indicate that at 95% credibility there is no difference between the

225 effectiveness of the two vaccine products (Table A5). Specifically, two doses of ChAdOx1 reduce

transmission from an Alpha variant case by 35% (-26%, 74%) and from a Delta variant case by

42% (14%, 69%).

Table 1: Median vaccine effectiveness (VE) and 95% credible intervals for infection protection

#### in contacts and transmission reduction in cases, by variant, vaccine product, and number of

#### 230

doses.

Variant	Vaccine	Doses	VE infection	VE transmission
Alpha	ChAdOx1	1	3% (-38%, 39%)	-7% (-60%, 29%)
		2	26% (-39%, 73%)	35% (-26%, 74%)
	BNT162b2	1	53% (7%, 83%)	26% (-11%, 54%)
		2	71% (12%, 95%)	57% (5%, 85%)
Delta	ChAdOx1	1	2% (-19%, 31%)	14% (-11%, 52%)
		2	14% (-5%, 46%)	42% (14%, 69%)
	BNT162b2	1	4% (-21%, 44%)	9% (-16%, 49%)
		2	24% (-2%, 64%)	31% (-3%, 61%)

231

## 232 Secondary attack rates

The estimated secondary household attack rate among adults in an unvaccinated household was
49% (34%, 63%) for the Alpha variant and 81% (57%, 96%) for the Delta variant (Figure 2).

235





case and contact. Large numbers inside cells are the median SAR, with the small numbers
below and above corresponding to the 95% credible interval.

240 BNT162b2 is very effective against Alpha variant infection when either the case or contact are 241 vaccinated, and especially when both have received two doses (Figure 2). SARs for Delta variant 242 infection in unvaccinated case-contact pairs are substantially higher. Full (two dose) vaccination 243 with either vaccine is still effective against Delta infection when both the case and contact are 244 vaccinated, at least halving the SAR; e.g. case and contact both fully vaccinated with BNT162b2 245 has an SAR of 30% (13%, 57%). SARs for each combination of contact and case age, vaccine 246 history and variant lineage are given in the appendix (Figures A5, A6). Notably, the reduced 247 susceptibility to infection of (unvaccinated) under-18s results in SARs which are no greater than

those seen in adult contacts who have received two doses of ChAdOx1.

## 249 Sensitivity analysis

250 Sensitivity analysis was conducted by including the 16 index case-contact pairs with serial

251 intervals less than -2 days. This did not qualitatively change our results (Table A4). The absence

of informative priors on the protective vaccine effects against infection led some of the vaccine

effectiveness against infection in our study to be re-attributed to effectiveness against onward

transmission or to age effects. Figure A4 provides a comparison of the exponentiated regression
coefficients (odds ratios) for the vaccine effects for the main and sensitivity analyses as well as the
informative prior used.

### 257 Infection history dynamics

We estimate that within a week of symptom onset, the relative risk of testing PCR positive is near identical for vaccinated and unvaccinated participants. For cases infected with the Alpha variant, there was little difference in PCR positivity generally between vaccinated and unvaccinated cases while in cases infected with the Delta variant the proportion of participants with PCR detectable infection in participants fully vaccinated with BNT162b2 declined about 4 days before that in unvaccinated participants. At 2-3 days the effect in participants fully vaccinated with ChAdOx1 was slightly less pronounced.



Figure 3: PCR positivity by Variant and vaccination status for symptomatic infections (index
cases recruited from Pillar 2 testing and the symptomatic household contacts they infected).
Lines represent median trajectories, and the ribbon is the 95% credible interval.

## 269 **Discussion**

265

270 In this prospective household-based study of SARS-CoV-2 infection we showed that both the 271 ChAdOx1 and BNT162b2 vaccines are effective in reducing transmission of the Alpha and Delta 272 variants from those who develop breakthrough infections despite having received two doses. The estimated vaccine effectiveness against acquisition of a Delta infection in the household setting 273 was however low; 14% (-5%, 46%) and 24% (-2%, 64%) after two doses of ChAdOx1 and 274 275 BNT162b2 respectively. This is lower than that estimated from cases presenting for Pillar 2 276 testing in the community for which the effectiveness of two doses of ChAdOx1 against 277 symptomatic infection is estimated as 67.0% (61.3%, 71.8%) and 88.0% (85.3%, 90.1%) for 278 BNT162b2.<sup>18</sup> Effectiveness against acquisition of an Alpha infection in the household was 279 substantially higher in our study than that against Delta but still lower than that estimated from 280 Pillar 2 community testing. The lower protection against acquisition in the household likely 281 reflects the prolonged and intense exposure that occurs in this setting. Similarly, although the 282 effectiveness estimates against transmission were moderate at 42% (14%, 69%) and 31% (-3%, 61%)

283 after 2 doses of ChadOx1 and BNT16b2 respectively, the protective effect in those with 284 breakthrough infections may be higher in the community where exposure is less intense and of 285 shorter duration. The reduction in duration of PCR positivity in breakthrough infections 286 (average of 4 days shorter for the Delta variant for those infected after two doses of BNT162b2 287 and around 2-3 days for ChAdOx1) will also have more of an impact in the community than in 288 the household setting where generation times between infections are short – around 3.5 days for 289 the Delta variant.<sup>19</sup> Our household contacts were actively followed up with repeated swabbing 290 and showed the high secondary attack rates that occur in this setting; 81% for Delta infections in 291 unvaccinated households but that reduced to 25-40% in households where both index case and 292 contacts were fully vaccinated.

293 Our finding of a moderate level of protection against onward transmission from fully vaccinated 294 individuals , with either vaccine and against either variant, is in apparent contrast to a study that 295 similarly followed up contacts reported by the UK test and trace system prospectively, about 90% of whom were in the same household as the index case<sup>20</sup>. The study estimated a moderate effect of 296 297 vaccination against infection but no difference in secondary attack rates with the delta variant 298 between fully vaccinated and unvaccinated index cases (24% and 23% respectively). However, 299 such estimates were neither controlled for age nor vaccination status of the contact. Interestingly 300 only 4 out of 17 (24%) unvaccinated contacts were infected by fully vaccinated index cases, 301 whereas 8 out of 20 (40%) unvaccinated contacts were infected by unvaccinated index cases; a 302 reduction in transmission of 41% albeit based on very small numbers. Vaccine effectiveness 303 against onward transmission of 40 to 80% has been suggested by several retrospective observational studies using either information on the household structure <sup>4</sup> or contact tracing <sup>5 6</sup> 304 305 in combination with routine national COVID-19 notification systems to estimate reductions in 306 secondary attack rates from breakthrough infections. While observational studies are prone to biases introduced by testing behaviour particularly for mild disease manifestations, our study 307 combines prospectively collected data with a robust analytical framework to confirm that both 308 309 vaccines reduce transmissibility of breakthrough infections in fully vaccinated individuals. 310 Among symptomatic index cases and contacts, we found a lower rate of PCR positivity within

311 two weeks of symptom onset in all vaccinated groups (Figures 3 and A7). PCR positivity for 312 Delta declined fastest (4 days ahead of unvaccinated) in individuals fully vaccinated with 313 BNT162b2. These results largely mirror those in other studies that found enhanced clearance following vaccination,<sup>20</sup> but raise the question whether enhanced clearance can be the driving 314 mechanism for reduced transmission in a frequent contact household setting. Another 315 316 mechanism may be that while positivity with the highly sensitive PCR test is similar to that in the 317 unvaccinated, vaccination can reduce <sup>21</sup>both peak viral load<sup>3,22</sup> and viral shedding<sup>23</sup>, although such 318 effects have not been reported in all studies and may be masked by age effects<sup>20</sup>. <sup>24</sup>

319 Our study comes with limitations, most importantly the potential for misclassification of the 320 direction of transmission, the lack of inclusion of waning vaccine protection and the diversity of 321 vaccines lineages and age groups in the dataset. To minimise the potential for misclassification we 322 restrict the main analyses to only those putative transmission pairs where the there was no 323 evidence against direct transmission based on phylogenetic distance (which was available for 63% 324 of all putative transmission pairs) and where symptom onset in the contact did not pre-date that 325 of the index case by more than 2 days. If residual misclassification between infector and infected 326 remained this would re-attribute infection protection to transmission protection and vice versa. 327 We also did not include waning of vaccine protection in our analyses<sup>26</sup> In the analysed dataset the 328 longest reported time since vaccine receipt was 169 days. While some individuals in the analysis 329 have since become eligible for booster vaccination over concerns of waning protection some of 330 this potential effect will have been absorbed in our model in the age structuring because of the 331 strong correlation between age and timing of vaccine eligibility as per vaccine roll-out strategy in 332 the UK. Lastly, data collection spanned a period of multiple months during which Delta became 333 the dominant strain in circulation in the UK and included participants vaccinated with two 334 different vaccine products; thus requiring sub-strata analyses and reducing the effective sample size for each strata. We used a Bayesian model that allowed the borrowing of strength through the 335 336 model hierarchy, and priors allowing us to make us of the heterogeneity in risk factors and not only estimate vaccine effectiveness against transmission in these strata but simultaneously 337 338 estimate the difference in transmissibility in Alpha and Delta variants and the effectiveness of 339 partially completed dosing schedules. The use of informative priors was integral to disentangling

340	the confounded age and vaccine history effects which arose due to vaccine product prioritisation
341	and were exacerbated by low counts for case-contact vaccine history combinations.

- 342 Our findings provide robust evidence from a prospective study that vaccination with either
- 343 BNT162b2 or ChAdOx1 can help to substantially reduce, but not completely prevent,
- 344 household transmission with SARS-CoV-2. This highlights the importance of vaccines to limit
- 345 circulation of SARS-CoV-2 particularly in close and prolonged contact indoor settings. The
- 346 effectiveness of booster doses to further enhance protection against transmission will need to be
- evaluated to better understand the extent to which we can rely on vaccination for the control of
- 348 SARS-CoV-2 infection, particularly during winter seasons when most contacts occur in
- 349 households or household-like settings.

# 350 **Declaration of interests**

351 The authors declare no conflicts of interest.

# 352 Authors' contributions

EM developed the household transmission protocol; NA and JLB contributed to the study design; SF advised on the overall analytic approach; PW was responsible for developing and curating the database; CG, FK and CS assisted in data management; LL managed the team of study nurses; SC developed and conducted the Bayesian analysis; JH, SH and SC conducted the genomic analysis; SC, SF, EM and JH drafted the paper; SC and JH generated the tables and figures. All authors reviewed the manuscript prior to submission.

## 359 **Funding statement**

360 This study was funded by the UK Health Security Agency (formerly Public Health England) (an

- 361 executive agency of the Department of Health) as part of the COVID-19 response. Samuel
- 362 Clifford is funded by the UK Medical Research Council (MC\_PC\_19065 Covid 19:
- 363 Understanding the dynamics and drivers of the COVID-19 epidemic using real-time outbreak
- 364 analytics). Samuel Clifford and Stefan Flasche are funded by a Sir Henry Dale Fellowship funded

365 by the Wellcome Trust and the Royal Society (208812/Z/17/Z). Jada Hackman is funded by the

366 Nagasaki University-London School of Hygiene and Tropical Medicine Doctoral Programme

- 367 under the WISE scheme. EM receives support from the National Institute for Health Research
- 368 (NIHR) Health Protection Research Unit in Immunisation at the London School of Hygiene
- 369 and Tropical Medicine in partnership with the UKHSA (Grant Reference NIHR200929).

## 370 Data sharing

371 All analysis code is available from https://github.com/cmmid/hhSAR. The data necessary to

372 replicate results is available from the authors on request, subject to a data sharing agreement.

## 373 Governance

The household surveillance protocol was approved by the UKHSA Research Ethics and Governance Group as part of the portfolio of the UKHSA's enhanced surveillance activities in response to the pandemic. Oral informed consent for sampling and follow up was obtained by the nurses from household members who were free to decline to participate in the surveillance at any time. Consent for children was obtained by a parent or legal guardian. Only anonymised data were provided to non-UKHSA authors.

# 380 Acknowledgements

381 We thank the nurses in the Immunisation Department of the UK Health Security Agency who

recruited and followed up the households and the administrative staff who sent out the swabbing

383 kits to households and arranged for their collection. We also thank the staff of the Virus

384 Reference Department, Central Sequencing Laboratory and the Core Bioinformatics Team of

385 PHE Colindale who performed the molecular testing and sequencing. Sequencing was financially

- 386 supported in part by the COG-UK Consortium. COG-UK is supported by funding from the
- 387 Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National
- 388 Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome
- 389 Sanger Institute. The authors also wish to thank Prof. Neil Ferguson (Imperial College London)
- 390 and for his comments and questions about earlier versions of this analysis.

# 391 **References**

- 392 1. Ritchie, H. *et al.* Coronavirus pandemic (COVID-19). *Our World Data* (2020).
- 393 2. World Health Organization. *Landscape of observational study designs on the effectiveness of*
- 394 *COVID-19 vaccination*. https://www.who.int/publications/m/item/draft-landscape-of-
- 395 observational-study-designs-on-the-effectiveness-of-covid-19-vaccination (2021).
- 396 3. Chia, P. Y. et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-
- 397 breakthrough infections: a multi-center cohort study. (2021)
- 398 doi:10.1101/2021.07.28.21261295.
- 399 4. Prunas, O. *et al.* Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to
- 400 household contacts in Israel. (2021) doi:10.1101/2021.07.13.21260393.
- 401 5. Eyre, D. W. et al. The impact of SARS-CoV-2 vaccination on Alpha and Delta variant
- 402 *transmission*. 2021.09.28.21264260
- 403 https://www.medrxiv.org/content/10.1101/2021.09.28.21264260v2 (2021)
- 404 doi:10.1101/2021.09.28.21264260.
- 405 6. de Gier, B. et al. Vaccine effectiveness against SARS-CoV-2 transmission and infections among
- 406 household and other close contacts of confirmed cases, the Netherlands, February to May 2021.
- 407 *Eurosurveillance* **26**, (2021).
- 408 7. Miller, E. *et al.* Transmission of SARS-CoV-2 in the household setting: A prospective cohort
- study in children and adults in England. J. Infect. S0163445321003807 (2021)
- 410 doi:10.1016/j.jinf.2021.07.037.
- 411 8. The COVID-19 Genomics UK (COG-UK) consortium. An integrated national scale SARS-

412	CoV-2 genomic	surveillance netwo	ork. <i>Lancet</i>	t Microbe 1	l, e99–e100	(2020).
-----	---------------	--------------------	--------------------	-------------	-------------	---------

- 413 9. R Core Team. *R: A Language and Environment for Statistical Computing*. (R Foundation for
- 414 Statistical Computing, 2021).
- 415 10. Plummer, M. *rjags: Bayesian Graphical Models using MCMC*. (2019).
- 416 11. Hall, V. J. et al. COVID-19 vaccine coverage in health-care workers in England and
- 417 effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective,
- 418 multicentre, cohort study. *The Lancet* **397**, 1725–1735 (2021).
- 419 12. Wellcome Sanger Institute. COVID-19 Genomic Surveillance. https://covid19.sanger.ac.uk/
- 420 (2021).
- 421 13. Nick J Andrews, Julia Stowe, Mary EB Ramsay & Elizabeth Miller. Risk of venous thrombotic
- 422 events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2
- 423 COVID-19 vaccines: a national cohort study in England. *Lancet Reg. Health Eur.* (In press).
- 14. UK Government. All young people aged 16 and 17 in England to be offered vaccine by next
- 425 week. *GOV.UK* https://www.gov.uk/government/news/all-young-people-aged-16-and-17-in-
- 426 england-to-be-offered-vaccine-by-next-week (2021).
- 427 15. UK Department of Health and Social Care. Universal vaccination of children and young people
- 428 aged 12 to 15 years against COVID-19. *GOV.UK*
- 429 https://www.gov.uk/government/publications/universal-vaccination-of-children-and-young-
- 430 people-aged-12-to-15-years-against-covid-19 (2021).
- 431 16. Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in
- 432 England. *Science* (2021) doi:10.1126/science.abg3055.

- 433 17. Goldstein, E., Lipsitch, M. & Cevik, M. On the Effect of Age on the Transmission of SARS-
- 434 CoV-2 in Households, Schools, and the Community. J. Infect. Dis. 223, 362–369 (2021).
- 435 18. Lopez Bernal, J. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
- 436 *N. Engl. J. Med.* (2021) doi:10.1056/nejmoa2108891.
- 437 19. Hart, W. et al. Generation time of the Alpha and Delta SARS-CoV-2 variants.
- 438 http://medrxiv.org/lookup/doi/10.1101/2021.10.21.21265216 (2021)
- 439 doi:10.1101/2021.10.21.21265216.
- 440 20. Singanayagam, A. *et al.* Community transmission and viral load kinetics of the SARS-CoV-2
- delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective,
- 442 longitudinal, cohort study. *Lancet Infect. Dis.* \$1473309921006484 (2021) doi:10.1016/\$1473-
- 443 3099(21)00648-4.
- 444 21. Regev-Yochay, G. et al. Decreased infectivity following BNT162b2 vaccination: A prospective
- 445 cohort study in Israel. *Lancet Reg. Health Eur.* 7, 100150 (2021).
- 446 22. Levine-Tiefenbrun, M. *et al.* Initial report of decreased SARS-CoV-2 viral load after
- 447 inoculation with the BNT162b2 vaccine. *Nat. Med.* **27**, 790–792 (2021).
- 448 23. Shamier, M. C. *et al.* Virological characteristics of SARS-CoV-2 vaccine breakthrough
- 449 infections in health care workers. (2021) doi:10.1101/2021.08.20.21262158.
- 450 24. Pritchard, E. et al. Impact of vaccination on new SARS-CoV-2 infections in the United
- 451 Kingdom. Nat. Med. (2021) doi:10.1038/s41591-021-01410-w.
- 452 25. Lee, L. Y. W. *et al.* Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- 453 Infectivity by Viral Load, S Gene Variants and Demographic Factors, and the Utility of Lateral

- 454 Flow Devices to Prevent Transmission. *Clin. Infect. Dis.* (2021) doi:10.1093/cid/ciab421.
- 455 26. Thomas, S. J. et al. Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19
- 456 *Vaccine*. http://medrxiv.org/lookup/doi/10.1101/2021.07.28.21261159 (2021)
- 457 doi:10.1101/2021.07.28.21261159.